Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Flea markets

This article was originally published in The Tan Sheet

Executive Summary

Pennsylvania House bill 1856 prohibiting the sale of "baby food, cosmetics or personal care products or any nonprescription drug or medical device" at swap meets or flea markets passes House Judiciary Committee Oct. 5. The bill was introduced because of concerns that outdated materials were being sold at such events. The bill has received support from the Pharmaceutical Research & Manufacturers of America as well as the Pennsylvania Retailers Association; similar legislation has passed in Indiana (1"The Tan Sheet" May 10, p. 19)

You may also be interested in...

Indiana flea market sales

Bill prohibiting the sale of OTCs, personal care products, cosmetics and medical devices in flea markets signed into law by Gov. Frank O'Bannon (R) May 3. Introduced by Rep. Michael Dvorak (D-St. Joseph), H 1495 passed the House 94-3 on Feb. 24 and the Senate floor 40-10 on April 12. The legislation was introduced for the first time earlier in the session. The Indiana Retail Association lobbied in favor of the bill's passage. A similar bill in Connecticut (No. 1103), which would restrict all sales of drugs, devices, cosmetics, baby food and infant formulas at flea markets, except if sold by a "manufacturer's or distributor's representative," is before the state's Joint Committee on Judiciary. A comparable bill also has been introduced in California ("The Tan Sheet" March 8, In Brief)

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts